An advanced understanding of the heterogeneous clinical features of “non-criteria” obstetric antiphospholipid syndrome: Two case reports and a literature review

Antiphospholipid syndrome (APS) is an acquired autoimmune disorder characterized by recurrent venous and/or arterial thrombosis and/or pregnancy complications, in the presence of elevated antiphospholipid (aPL) antibodies. APS in pregnant women is referred to as “obstetrical” APS (OAPS). The diagnosis of definite OAPS requires the presence of one or more typical clinical criteria and persistent aPL antibodies at least 12 weeks apart. However, the classification criteria for OAPS have generated wide discussion, with a growing impression that certain patients not fully meeting these criteria might be inappropriately excluded from the classification, which is known as “non-criteria” OAPS. We present here two unique cases of potentially lethal “non-criteria” OAPS, complicating severe preeclampsia, fetal growth restriction (FGR), liver rupture, preterm birth, refractory recurrent miscarriages, or even stillbirth. We further share our diagnostic search and analysis, treatment adjustment, and prognosis for this unusual antenatal event. We will also present a short review of an advanced understanding of the pathogenetic mechanisms of this disease, heterogeneous clinical features, and potential significance.

[1]  L. Magee,et al.  Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. , 2022, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[2]  J. Alijotas-Reig,et al.  Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review , 2022, Journal of clinical medicine.

[3]  L. Pedro,et al.  A catastrophic seronegative anti-phospholipid syndrome: case and literature review , 2021, Thrombosis Journal.

[4]  G. Espinosa,et al.  "Non-criteria" antiphospholipid syndrome: A nomenclature proposal. , 2020, Autoimmunity reviews.

[5]  Jyotsna Y. Rani,et al.  "Hepatic rupture in preeclampsia and HELLP syndrome: A catastrophic presentation". , 2020, Taiwanese journal of obstetrics & gynecology.

[6]  J. Biggio,et al.  Society for Maternal-Fetal Medicine (SMFM) Consult Series #52: Diagnosis and Management of Fetal Growth Restriction. , 2020, American journal of obstetrics and gynecology.

[7]  D. Branch,et al.  What's new in obstetric antiphospholipid syndrome. , 2019, Hematology. American Society of Hematology. Education Program.

[8]  anonymous,et al.  Comprehensive review , 2019 .

[9]  M. Ward,et al.  EULAR recommendations for the management of antiphospholipid syndrome in adults , 2019, Annals of the rheumatic diseases.

[10]  D. Branch,et al.  Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study , 2018, Lupus.

[11]  D. Garcia,et al.  Diagnosis and Management of the Antiphospholipid Syndrome , 2018, The New England journal of medicine.

[12]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[13]  L. Carbillon,et al.  Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: Prevalence and treatment efficacy in pregnancies. , 2016, Seminars in arthritis and rheumatism.

[14]  M. Petri,et al.  The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. , 2015, Autoimmunity reviews.

[15]  H. Cohen,et al.  Diagnosis and management of non-criteria obstetric antiphospholipid syndrome , 2014, Thrombosis and Haemostasis.

[16]  J. Gris,et al.  Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients , 2009, Annals of the rheumatic diseases.

[17]  C. Palmiere,et al.  Fatal intrahepatic hemorrhage after nadroparin use for total hip arthroplasty , 2014, Forensic Science, Medicine, and Pathology.

[18]  M. Khamashta,et al.  Seronegative antiphospholipid syndrome. , 2013, Rheumatology.

[19]  M. Khamashta,et al.  Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’) , 2011, Annals of the rheumatic diseases.

[20]  Y. Shoenfeld,et al.  HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. , 2011, Seminars in arthritis and rheumatism.

[21]  M. Rodger,et al.  The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. , 2011, Thrombosis research.

[22]  A. Odibo,et al.  Diagnosis and Management of Fetal Growth Restriction , 2011, Journal of pregnancy.

[23]  J. Piette,et al.  Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients , 2008, Annals of the rheumatic diseases.

[24]  R. Cervera,et al.  Microangiopathic antiphospholipid-associated syndromes revisited new concepts relating to antiphospholipid antibodies and syndromes. , 2007, The Journal of rheumatology.

[25]  F. Vancheri,et al.  Hepatic artery aneurysm rupture in a woman with primary antiphospholipid syndrome , 2007, Lupus.

[26]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[27]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[28]  G. Hughes,et al.  Seronegative antiphospholipid syndrome , 2003, Annals of the rheumatic diseases.